Login to Your Account



Too Big to Fail

CNS Goal: Happier Endings, Smarter Starts, Better Trials

By Anette Breindl
Science Editor

Monday, March 19, 2012

With big pharma's flight from central nervous system (CNS) drug discovery, one conclusion of a recent Tufts report seems surprising on first read: The CNS new product pipeline is among the richest in the research-based drug industry.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription